Home Add to Favorite Contact Submit  
           29 March, 2024


    
Category:  Press » Software

 

Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals

Popularity:
         Views: 1650
2008-06-10 03:20:46     
Nuevolution A/S

Nuevolution A/S today announced a strategic alliance with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) aimed at the discovery of novel small molecule lead compounds for highly validated drug targets.

Under the terms of the alliance, Nuevolution's proprietary Chemetics(R) drug discovery technology will be applied to identify novel small molecule lead compounds against a range of drug targets proposed by Lexicon. Nuevolution will receive an upfront payment and will be eligible for milestone payments and royalties on compounds identified using its technology as candidate molecules progress through preclinical and clinical development and onto the market. At a future point in time, Nuevolution will have the option to expand its involvement in certain programs under a cost and profit sharing arrangement.

The collaboration will harness the power of Nuevolution's Chemetics(R) platform technology which enables both hit identification and hit-to-lead optimization by exploration of ultra large chemistry space through the screening of multiple fragment-based small molecule libraries of more than 100 million compounds per library.

The validated targets have been identified through Lexicon's Genome5000TM program where the company explored the physiological and behavioral function for nearly 5,000 human genes by studying the corresponding mouse genes in knockout animals. This endeavor led to the identification of more than 100 highly validated drug targets that Lexicon is using to build a unique and growing clinical pipeline.

"Our proprietary Chemetics(R) platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale," said Alex Gouliaev, CEO of Nuevolution A/S. "We believe this generates high quality hits and leads far more rapidly and reliably than current ultra high throughput methods. Combining our platform with Lexicon's highly validated target portfolio represents an exceptional drug discovery opportunity and we very much look forward to bringing together Lexicon's expertise in biology and ours in chemistry, creating a synergistic biotech alliance."

"This important alliance is designed to accelerate Lexicon's ability to move from novel knockout validated targets to drug candidates as we continue to build our pipeline of innovative products," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer of Lexicon.

About Nuevolution

Nuevolution is a leading drug discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Venture and Novo A/S.

For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Co., Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Specialized in: Lexicon - Breakthrough - Gene - Biotech - Genome - Knockout - Mice
URL: http://www.lexpharma.com
Print press release      Bookmark this page
Related Press releases 
The newest release of a complete database development tool "Database Workbench" has arrived! (Popularity: ): Berghem (press.abc-directory ) - October 18th, 2022 - Upscene Productions has launched the latest edition of its flagship software, Database Workbench.This release brings support for the latest MariaDB and Oracle versions, as well as additional features for other database systems. The initial version 6 includes many improvements to the user interface and existing tools, it also brought full Firebird 4 support, PostgreSQL table inheritance and Oracle multi-segmented expression indices support.What's new ...
Axle.ai Launches Connectr 2021 Software for Windows, Mac and Linux (Popularity: ): New Windows version of NoCode workflow tool significantly broadens market.Boston, MA - USA, December 20, 2021 -- Axle.ai, the leader in bringing radical simplicity to video search and collaboration, announced availability of Connectr 2021, its revolutionary NoCode software for automating media workflows, for Windows, MacOS and Linux. The company is a Silver sponsor at the Adobe MAX virtual conference, which starts today.Connectr 2021 is available for all 3 platforms and ...
Frederick Custom Software Company Discusses ERP Software Solutions (Popularity: ): Frederick, Maryland ( press.abc-directory.com ) May 31, 2021 - Orases, a Frederick, Maryland custom software development company, recently released a new educational resource that focuses on explaining the details of ERP software solutions and how they work to increase organizational efficiency. The new article is guided by the software development professionals at Orases who have a deep understanding of ERP software solutions and how they can be valuable for businesses. ...
ACD Systems Launches Photo Studio Ultimate 2021, Inspired by its Customers (Popularity: ): VICTORIA, BC (November 8, 2020) - Today, ACD Systems International launches ACDSee Photo Studio Ultimate 2021, the latest version of their flagship innovative photo editing software.This year, there's been a huge focus on optimizing the experience for photographers. Performance enhancements make processes up to 100% faster. RAW decoding is up to 20% faster.New features focus on optimizing editing precision and batch processes that make the life of photographers easier."This product ...
Maryland Custom Software Development Company Educates On SaaS (Popularity: ): Frederick, Maryland ( press.abc-directory.com ) October 25, 2020 - Orases, a Maryland custom software development company, recently released a new educational resource on its website that discusses SaaS vs. custom software development. The new article is guided by the expert software developers at Orases who understand the difference between SaaS programs and getting custom software development done. They hope this new article will help readers understand the difference between these ...


Related Business 
Information About Drugs, Drug Use and Vitamins (Popularity: ): Read our articles on the topics of drug rehabilitation, drug therapy and drug counseling. The major drug - lexicon is a list of words on the subject of drugs, drugs and addiction. There are different types of drugs. Known drugs are alcohol, nicotine, cannabis, ecstasy, hallucinogenic, cocaine, opiates and speed.
Karo Bio AB (Popularity: ): A drug discovery company focusing its research on the discovery and pre-clinical phases of drug development.
Alantos Pharmaceuticals AG (Popularity: ): Company using target amplified drug candidate evolution platform for discovery. Includes profile, news, and career contacts in Heidelberg, Germany.
IBC's Drug Discovery Technology 2002 (Popularity: ): Drug discovery techniques. August 4-9, 2002 in Boston, MA, USA.
Prolexys Pharmaceuticals (Popularity: ): Prolexys uses pioneering high throughput proteomics technologies to map protein-protein interactions and identify new targets for drug discovery
Arena Pharmaceuticals, Inc. (Popularity: ): Receptor-based drug discovery in the fields of diabetes, obesity, cardiovascular, sleep disorders, neurodegeneration, schizophrenia, depression and anxiety. Comprehensive profile of company in San Diego, California. (Nasdaq: ARNA)
Discovery Partners International (Popularity: ): Discovery Partners International is the premier provider of technology, products and services that augment the drug discovery efforts of the pharmaceutical industry.
Discovery Partners International (Popularity: ): Provider of technology, products and services that augment the drug discovery efforts of the pharmaceutical industry.
Active Pharmaceuticals Ingredients (Popularity: ): Yashica Pharmaceuticals Private Limited is one of the most trusted & leading manufacturers and exporters of pharmaceutical raw materials, drug intermediates, specialty chemicals and pharmaceutical excipients. Incorporated in the year 2007, under the visionary Mr. Sanjay Totre, today Yashica Pharmaceuticals has evolved as a pioneer in pharmaceutical drugs worldwide.
Drug Policy Alliance (Popularity: ): Broaden debate and promote alternatives to drug war. Formerly known as The Lindesmith Center - Drug Policy Foundation. Guiding principle is harm reduction.